Walsky RL[au] - Search Results

Year	Number of Results
2003	1
2004	2
2005	6
2006	4
2007	3
2008	3
2009	2
2011	2
2012	3
2013	2
2014	2
2015	2
2018	1
2020	1
2021	1
2023	0

1

In vitro cytochrome P450 inhibition and induction.

Walsky RL, Boldt SE. Walsky RL, et al. Curr Drug Metab. 2008 Nov;9(9):928-39. doi: 10.2174/138920008786485128. Curr Drug Metab. 2008. PMID: 18991590 Review.

2

Pharmacokinetics of the natural antibiotic negamycin.

Guo J, Miele EW, Chen A, Luzietti RA, Zambrowski M, Walsky RL, Buurman ET. Guo J, et al. Among authors: walsky rl. Xenobiotica. 2015;45(7):625-33. doi: 10.3109/00498254.2015.1006301. Epub 2015 Mar 3. Xenobiotica. 2015. PMID: 25733027

3

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach.

Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. Obach RS, et al. Among authors: walsky rl. Clin Pharmacol Ther. 2005 Dec;78(6):582-92. doi: 10.1016/j.clpt.2005.09.004. Clin Pharmacol Ther. 2005. PMID: 16338274 Review. No abstract available.

4

Discovery of M5049: A Novel Selective Toll-Like Receptor 7/8 Inhibitor for Treatment of Autoimmunity.

Vlach J, Bender AT, Przetak M, Pereira A, Deshpande A, Johnson TL, Reissig S, Tzvetkov E, Musil D, Morse NT, Haselmayer P, Zimmerli SC, Okitsu SL, Walsky RL, Sherer B. Vlach J, et al. Among authors: walsky rl. J Pharmacol Exp Ther. 2021 Mar;376(3):397-409. doi: 10.1124/jpet.120.000275. Epub 2020 Dec 16. J Pharmacol Exp Ther. 2021. PMID: 33328334

5

Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor.

Walsky RL, Obach RS. Walsky RL, et al. Drug Metab Dispos. 2003 Mar;31(3):343. doi: 10.1124/dmd.31.3.343. Drug Metab Dispos. 2003. PMID: 12625332 No abstract available.

6

Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers.

Keirstead ND, Wagoner MP, Bentley P, Blais M, Brown C, Cheatham L, Ciaccio P, Dragan Y, Ferguson D, Fikes J, Galvin M, Gupta A, Hale M, Johnson N, Luo W, McGrath F, Pietras M, Price S, Sathe AG, Sasaki JC, Snow D, Walsky RL, Kern G. Keirstead ND, et al. Among authors: walsky rl. Toxicol Sci. 2014 Feb;137(2):278-91. doi: 10.1093/toxsci/kft247. Epub 2013 Nov 4. Toxicol Sci. 2014. PMID: 24189134

7

Validated assays for human cytochrome P450 activities.

Walsky RL, Obach RS. Walsky RL, et al. Drug Metab Dispos. 2004 Jun;32(6):647-60. doi: 10.1124/dmd.32.6.647. Drug Metab Dispos. 2004. PMID: 15155557

8

Selective inhibition of human cytochrome P4502C8 by montelukast.

Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR. Walsky RL, et al. Drug Metab Dispos. 2005 Mar;33(3):413-8. doi: 10.1124/dmd.104.002766. Epub 2004 Dec 17. Drug Metab Dispos. 2005. PMID: 15608135

9

Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.

Moller RA, Fisher JM, Taylor AE, Kolluri S, Gardner MJ, Obach RS, Walsky RL. Moller RA, et al. Among authors: walsky rl. Ann Pharmacother. 2006 Jan;40(1):32-7. doi: 10.1345/aph.1G347. Epub 2005 Dec 20. Ann Pharmacother. 2006. PMID: 16368922 Clinical Trial.

10

Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

Walsky RL, Astuccio AV, Obach RS. Walsky RL, et al. J Clin Pharmacol. 2006 Dec;46(12):1426-38. doi: 10.1177/0091270006293753. J Clin Pharmacol. 2006. PMID: 17101742

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results